Claims
- 1. A method for characterizing prostate tissue in a subject, comprising:
a) providing a prostate tissue sample from a subject; and b) detecting the presence or absence of expression of hepsin in said sample, thereby characterizing said prostate tissue sample.
- 2. The method of claim 1, wherein said detecting the presence of expression of hepsin comprises detecting the presence of hepsin mRNA.
- 3. The method of claim 2, wherein said detecting the presence of expression of hepsin mRNA comprises exposing said hepsin mRNA to a nucleic acid probe complementary to said hepsin mRNA.
- 4. The method of claim 1, wherein said detecting the presence of expression of hepsin comprises detecting the presence of a hepsin polypeptide.
- 5. The method of claim 4, wherein said detecting the presence of a hepsin polypeptide comprises exposing said hepsin polypeptide to an antibody specific to said hepsin polypeptide and detecting the binding of said antibody to said hepsin polypeptide.
- 6. The method of claim 1, wherein said subject comprises a human subject.
- 7. The method of claim 1, wherein said sample comprises tumor tissue.
- 8. The method of claim 7, wherein said tumor tissue sample is a post-surgical tumor tissue sample and said method further comprises the step of c) identifying a risk of prostate specific antigen failure based on said detecting the presence or absence of expression of hepsin.
- 9. The method of claim 1, wherein said characterizing said prostate tissue comprises identifying a stage of prostate cancer in said prostate tissue.
- 10. The method of claim 9, wherein said stage is selected from the group consisting of high-grade prostatic intraepithelial neoplasia, benign prostatic hyperplasia, prostate carcinoma, and metastatic prostate carcinoma.
- 11. The method of claim 1, further comprising the step of c) providing a prognosis to said subject.
- 12. The method of claim 11, wherein said prognosis comprises a risk of developing prostate specific antigen failure.
- 13. The method of claim 12, wherein said prognosis comprises a risk of developing prostate cancer.
- 14. A method for characterizing prostate tissue in a subject, comprising:
a) providing a prostate tissue sample from a subject; and b) detecting the presence or absence of expression of pim-1 in said sample, thereby characterizing said prostate tissue sample.
- 15. The method of claim 14, wherein said detecting the presence of expression of pim-1 comprises detecting the presence of pim-1 mRNA.
- 16. The method of claim 15, wherein said detecting the presence of expression of pim-1 mRNA comprises exposing said pim-1 mRNA to a nucleic acid probe complementary to said pim-1 mRNA.
- 17. The method of claim 14, wherein said detecting the presence of expression of pim-1 comprises detecting the presence of a pim-1 polypeptide.
- 18. The method of claim 17, wherein said detecting the presence of a pim-1 polypeptide comprises exposing said pim-1 polypeptide to an antibody specific to said pim-1 polypeptide and detecting the binding of said antibody to said pim-1 polypeptide.
- 19. The method of claim 14, wherein said subject is a human subject.
- 20. The method of claim 14, wherein said sample comprises tumor tissue.
- 21. The method of claim 20, wherein said tumor tissue is post-surgical tumor tissue and said method further comprises the step of c) identifying a risk of prostate specific antigen failure based on said detecting the presence or absence of expression of hepsin.
- 22. The method of claim 14, wherein said characterizing said prostate tissue comprises detecting a stage of prostate cancer in said prostate tissue.
- 23. The method of claim 22, wherein said stage is selected from the group consisting of high-grade prostatic intraepithelial neoplasia, benign prostatic hyperplasia, prostate carcinoma, and metastatic prostate carcinoma.
- 24. The method of claim 14, further comprising the step of c) providing a prognosis to said subject.
- 25. The method of claim 24, wherein said prognosis comprises a risk of developing prostate specific antigen failure.
- 26. The method of claim 24, wherein said prognosis comprises a risk of developing prostate cancer.
- 27. A method for characterizing prostate tissue in a subject, comprising:
a) providing a prostate tissue sample from a subject; and b) detecting the presence or absence of expression of EZH2 in said sample, thereby characterizing said prostate tissue sample.
- 28. The method of claim 27, wherein said detecting the presence of expression of EZH2 comprises detecting the presence of EZH2 mRNA.
- 29. The method of claim 28, wherein said detecting the presence of expression of hepsin mRNA comprises exposing said hepsin mRNA to a nucleic acid probe complementary to said hepsin mRNA.
- 30. The method of claim 27, wherein said detecting the presence of expression of EZH2 comprises detecting the presence of a EZH2 polypeptide.
- 31. The method of claim 30, wherein said detecting the presence of a EZH2 polypeptide comprises exposing said EZH2 polypeptide to an antibody specific to said EZH2 polypeptide and detecting the binding of said antibody to said EZH2 polypeptide.
- 32. The method of claim 27, wherein said subject comprises a human subject.
- 33. The method of claim 27, wherein said sample comprises tumor tissue.
- 34. The method of claim 27, wherein said characterizing said prostate tissue comprises identifying a stage of prostate cancer in said prostate tissue.
- 35. The method of claim 34, wherein said stage is selected from the group consisting of high-grade prostatic intraepithelial neoplasia, benign prostatic hyperplasia, prostate carcinoma, and metastatic prostate carcinoma.
- 36. The method of claim 27, further comprising the step of c) providing a prognosis to said subject.
- 37. The method of claim 36, wherein said prognosis comprises a risk of developing metastatic prostate cancer.
- 38. A kit for characterizing prostate cancer in a subject, comprising:
a) a reagent capable of specifically detecting the presence of absence of expression of hepsin; and d) instructions for using said kit for characterizing cancer in said subject.
- 39. The kit of claim 38, wherein said reagent comprises a nucleic acid probe complementary to a hepsin mRNA.
- 40. The kit of claim 38, wherein said reagent comprises an antibody that specifically binds to a hepsin polypeptide.
- 41. The kit of claim 38, wherein said instructions comprise instructions required by the United States Food and Drug Administration for use in in vitro diagnostic products.
- 42. A kit for characterizing prostate cancer in a subject, comprising:
a) a reagent capable of specifically detecting the presence of absence of expression of pim-1; and d) instructions for using said kit for characterizing cancer in said subject.
- 43. The kit of claim 42, wherein said reagent comprises a nucleic acid probe complementary to a pim-1 mRNA.
- 44. The kit of claim 42, wherein said reagent comprises an antibody that specifically binds to a pim-1 polypeptide.
- 45. The kit of claim 42, wherein said instructions comprise instructions required by the United States Food and Drug Administration for use in in vitro diagnostic products.
- 46. A kit for characterizing prostate cancer in a subject, comprising:
a) a reagent capable of specifically detecting the presence of absence of expression of EZH2; and d) instructions for using said kit for characterizing cancer in said subject.
- 47. The kit of claim 46, wherein said reagent comprises a nucleic acid probe complementary to a EZH2 mRNA.
- 48. The kit of claim 46, wherein said reagent comprises an antibody that specifically binds to a EZH2 polypeptide.
- 49. The kit of claim 46, wherein said instructions comprise instructions required by the United States Food and Drug Administration for use in in vitro diagnostic products.
- 50. A method of screening compounds, comprising:
a) providing
i) a prostate cell sample; and ii) one or more test compounds; and b) contacting said prostate cell sample with said test compound; and c) detecting a change in hepsin expression in said prostate cell sample in the presence of said test compound relative to the absence of said test compound.
- 51. The method of claim 50, wherein said detecting comprises detecting hepsin mRNA.
- 52. The method of claim 50, wherein said detecting comprises detecting hepsin polypeptide.
- 53. The method of claim 50, wherein said cell is in vitro.
- 54. The method of claim 50, wherein said cell is in vivo.
- 55. The method of claim 50, wherein said test compound comprises an antisense compound.
- 56. The method of claim 50, wherein said test compound comprises a drug.
- 57. A method of screening compounds, comprising:
a) providing
i) a prostate cell sample; and ii) one or more test compounds; and b) contacting said prostate cell sample with said test compound; and c) detecting a change in pim-1 expression in said prostate cell sample in the presence of said test compound relative to the absence of said test compound.
- 58. The method of claim 57, wherein said detecting comprises detecting pim-1 mRNA.
- 59. The method of claim 57, wherein said detecting comprises detecting pim-1 polypeptide.
- 60. The method of claim 57, wherein said cell is in vitro.
- 61. The method of claim 57, wherein said cell is in vivo.
- 62. The method of claim 57, wherein said test compound comprises an antisense compound.
- 63. The method of claim 57, wherein said test compound comprises a drug.
- 64. A method of screening compounds, comprising:
a) providing
i) a prostate cell sample; and ii) one or more test compounds; and b) contacting said prostate cell sample with said test compound; and c) detecting a change in EZH2 expression in said prostate cell sample in the presence of said test compound relative to the absence of said test compound.
- 65. The method of claim 64, wherein said detecting comprises detecting EZH2 mRNA.
- 66. The method of claim 64, wherein said detecting comprises detecting EZH2 polypeptide.
- 67. The method of claim 64, wherein said cell is in vitro.
- 68. The method of claim 64, wherein said cell is in vivo.
- 69. The method of claim 64, wherein said test compound comprises an antisense compound.
- 70. The method of claim 64, wherein said test compound comprises a drug.
- 71. A method for characterizing inconclusive prostate biopsy tissue in a subject, comprising:
a) providing an inconclusive prostate biopsy tissue sample from a subject; and b) detecting the presence of expression of AMACR in said sample, thereby characterizing said inconclusive prostate biopsy tissue sample.
- 72. The method of claim 71, wherein said detecting the presence of expression of AMACR comprises detecting the presence of AMACR mRNA.
- 73. The method of claim 72, wherein said detecting the presence of expression of AMACR mRNA comprises exposing said AMACR mRNA to a nucleic acid probe complementary to at least a portion of said AMACR mRNA.
- 74. The method of claim 71, wherein said detecting the presence of expression of AMACR comprises detecting the presence of a AMACR polypeptide.
- 75. The method of claim 74, wherein said detecting the presence of a AMACR polypeptide comprises exposing said AMACR polypeptide to an antibody specific to said AMACR polypeptide and detecting the binding of said antibody to said AMACR polypeptide.
- 76. The method of claim 71, wherein said subject comprises a human subject.
- 77. The method of claim 71, wherein the presence of AMACR expression in said inconclusive biopsy tissue is indicative of prostate cancer in said subject.
- 78. The method of claim 71, wherein said method further comprises the step of detecting expression of a basal cell marker selected from the group consisting of 34βE12 and p63 and the absence of a basal cell marker expression and the presence of AMACR expression is indicative of prostate cancer in said subject.
- 79. A method of detecting AMACR expression in a bodily fluid, comprising:
a) providing
i) a bodily fluid from a subject; and ii) a reagent for detecting AMACR expression in said biological fluid; and b) contacting said bodily fluid with said reagent under conditions such that said reagent detects AMACR expression in said bodily fluid.
- 80. The method of claim 79, wherein said bodily fluid is selected from the group consisting of serum, urine, whole blood, lymph fluid, and mucus.
- 81. The method of claim 79, wherein the presence of AMACR in said bodily fluid is indicative of cancer.
- 82. The method of claim 79, wherein said cancer is prostate cancer.
- 83. A kit for characterizing inconclusive prostate biopsy tissue in a subject, comprising:
a) a reagent capable of specifically detecting the presence or absence of expression of AMACR; and b) instructions for using said kit for characterizing inconclusive biopsy tissue in said subject.
- 84. The kit of claim 83, wherein said reagent comprises a nucleic acid probe complementary to at least a portion of an AMACR mRNA.
- 85. The kit of claim 83, wherein said reagent comprises an antibody that specifically binds to a AMACR polypeptide.
- 86. The kit of claim 83, wherein said kit further comprises a second reagent, said second reagent capable of specifically detecting the expression of a basal cell marker selected from the group consisting of 34βE12 and p63.
- 87. The kit of claim 86, wherein said instructions further comprise instructions for using said second reagent and said reagent for characterizing inconclusive biopsy tissue in said subject.
- 88. The kit of claim 83, wherein said instructions comprise instructions required by the United States Food and Drug Administration for use in in vitro diagnostic products.
- 89. A method of characterizing tissue in a subject, comprising:
a) providing a tissue sample from a subject, said tissue sample selected from the group consisting of breast tissue, ovarian tissue, lymph tissue, and melanoma tissue; and b) detecting the presence or absence of expression of AMACR in said sample, thereby characterizing said breast tissue sample.
- 90. A method of diagnosing cancer in a subject, comprising:
a) providing a tissue sample from a subject, said tissue sample selected from the group consisting of breast tissue, ovarian tissue, lymph tissue, and melanoma tissue; and wherein said subject is suspected of having breast cancer; and b) detecting the presence of expression of AMACR in said sample, thereby diagnosing cancer in said subject.
- 91. A method of diagnosing cancer in a subject, comprising:
a) providing a blood sample from a subject suspected of having cancer; and b) detecting an immune response to AMACR in said blood sample, thereby diagnosing cancer in said subject.
- 92. The method of claim 91, wherein said cancer is prostate cancer.
- 93. The method of claim 91, wherein said detecting an immune response comprises detecting an antibody against said AMACR in said blood sample.
- 94. A method of inhibiting the growth of cells, comprising
a) providing
i) a cell that expresses EZH2; and i) a reagent for inhibiting EZH2 expression in said cell; and b) contacting said cell with said reagent under conditions such that the expression of EZH2 in said cell is inhibited.
- 95. The method of claim 94, wherein said reagent is an antisense oligonucleotide.
- 96. The method of claim 94, wherein said reagent is a RNA duplex.
- 97. The method of claim 94, wherein said reagent is a drug.
- 98. The method of claim 94, wherein said cell is a prostate cancer cell.
- 99. The method of claim 94, wherein said cell is in vitro.
- 100. The method of claim 94, wherein said cell is in vivo.
- 101. The method of claim 94, wherein said contacting further results in a decrease in proliferation of said cell.
Parent Case Info
[0001] This application claims priority to U.S. Provisional Application Serial No. 60/309,581 filed Aug. 2, 2001 and U.S. Provisional Application Serial No. 60/334,468 filed Nov. 15, 2001.
Government Interests
[0002] This invention was made with government support under Grant No. 5 P50 CA69568 awarded by the National Institutes of Health. The Government has certain rights in the invention.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60309581 |
Aug 2001 |
US |
|
60334468 |
Nov 2001 |
US |